For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
19
views
21
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      356
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives:

          In this study we retrospectively analyzed the prognostic factors of patients with advanced non-small cell lung cancer (NSCLC).

          Methods:

          Clinical data of 112 patients with advanced NSCLC treated in the tumor center of our hospital from January 2016 to December 2017 were analyzed retrospectively, follow up the survival of patients, the effects of gender, age, tumor stage, pathological type, performance status (PS) score, smoking history and treatment on the survival of elderly patients with advanced NSCLC were analyzed.

          Results: The median survival time was 12.0 months, and the median age was 74 years. The 3-year survival rate after confirmation of advanced lung cancer was 6.25%. Kaplan Meier univariate analysis showed that age, PS score, smoking status and treatment correlated with the prognosis( P<0.05). Cox multivariate analysis showed that age >70 years, PS score>2, smoking and no targeted therapy were independent adverse prognostic factors for elderly patients with advanced NSCLC( P<0.05).

          Conclusions:

          Age, PS score, smoking and treatment mode affect the prognosis and survival of elderly patients with advanced NSCLC. Effective treatment should be given according to the principle of evidence-based medicine.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

          Narjust Duma, Rafael Santana-Davila, Julian R. Molina (2019)
          Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.
          Article 0 comments Cited 756 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

            Kathryn Arbour, Gregory J. Riely (2019)
            Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients with advanced or metastatic disease.
            Article 0 comments Cited 440 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lung Cancer

              Faria Nasim, Bruce F Sabath, George Eapen (2019)
              Lung cancer is the world's leading cause of cancer death. Screening for lung cancer by low-dose computed tomography improves mortality. Various modalities exist for diagnosis and staging. Treatment is determined by subtype and stage of cancer; there are several personalized therapies that did not exist just a few years ago. Caring for the patient with lung cancer is a complex task. This review provides a broad outline of this disease, helping clinicians identify such patients and familiarizing them with lung cancer care options, so they are better equipped to guide their patients along this challenging journey.
              Article 0 comments Cited 318 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Pak J Med Sci
                Journal ID (iso-abbrev): Pak J Med Sci
                Title: Pakistan Journal of Medical Sciences
                Publisher: Professional Medical Publications (Pakistan )
                ISSN (Print): 1682-024X
                ISSN (Electronic): 1681-715X
                Publication date (Print): Jul-Aug 2022
                Volume: 38
                Issue: 6
                Pages: 1674-1679
                Affiliations
                [1 ]Fanglan Ran, Department of Respiratory and Critical Care Medicine, Chongqing University Fuling Hospital, 2 Gaosuntang Road, Chongqing 408000, P.R. China
                [2 ]Qin Liu, Department of Respiratory and Critical Care Medicine, Chongqing University Fuling Hospital, 2 Gaosuntang Road, Chongqing 408000, P.R. China
                Author notes
                Correspondence: Qin Liu, Department of Respiratory and Critical Care Medicine, Chongqing University Fuling Hospital, 2 Gaosuntang Road, Chongqing 408000, P.R. China. E-mail: qliu1982@ 123456126.com
                Article
                Publisher ID: PJMS-38-1674
                DOI: 10.12669/pjms.38.6.5457
                PMC ID: 9378386
                PubMed ID: 35991233
                SO-VID: fb6c7c37-ecbe-4ee4-82ea-69ba43b833f7
                Copyright © Copyright: © Pakistan Journal of Medical Sciences
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 08 September 2021
                Date revision received : 03 October 2021
                Date revision received : 09 February 2022
                Date accepted : 28 February 2022
                Categories
                Subject: Original Article

                Keywords: advanced,non-small cell lung cancer,prognostic factors,median survival time,retrospective analysis
                Data availability:
                Keywords: advanced, non-small cell lung cancer, prognostic factors, median survival time, retrospective analysis

                Comments

                Comment on this article

                scite_

                Similar content356

                See all similar

                Cited by3

                See all cited by

                Most referenced authors303

                See all reference authors